SARS-CoV-2 specific cytotoxic T lymphocytes (M.D. Anderson Cancer Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameSARS-CoV-2 specific cytotoxic T lymphocytes (M.D. Anderson Cancer Center)
Drug Alias NameSARS-CoV-2 antigen-specific CTLs (M.D. Anderson Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultPneumonia, Viral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultPneumonia, Viral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A